Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.

TAK-580: An Oral Pan-RAF Kinase Inhibitor

TAK-580 (formerly called MLN2480) is an oral pan-RAF kinase inhibitor with a distinct molecular signature which has exhibited a promising preclinical profile. TAK-580 was identified through a pan-RAF inhibitor discovery program that was originally initiated under a collaboration agreement between Sunesis and Biogen Idec. TAK-580 is currently being developed by Takeda Pharmaceutical Company Limited through an exclusive license from Sunesis, which includes an option for co-development by Sunesis.

Takeda is currently supporting a Phase 1b/2 clinical study of TAK-580 in pediatric low-grade glioma.

Under the license agreement, we may in the future receive pre-commercialization, event-based payments related to the development by Millennium of the first two indications for each of the licensed products directed against the RAF target, and royalty payments depending on related product sales.

For more information about TAK-580 clinical trials, please click here.


Download presentations that have been given at recent conferences and meetings.
TAK-580 (RAF) Presentations